Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is well-positioned to capitalize on the growing demand for treatments for obesity and related conditions with their innovative use of AI and ML in developing precision antibodies. Their strong pipeline of potential therapies for obesity and cardiometabolic diseases, combined with promising results in preclinical and early human studies, give a positive outlook for the company's future success. However, investors should keep in mind the potential challenges of competition and the need for continued funding in the biotechnology industry.

Bears say

iBio is a biotechnology company that has a diverse pipeline of potential treatments for rare diseases, with its new drug IBIO-610 showing promise in treating obesity and other health issues. The company is also in a strong financial position, but faces risks in clinical trials and protecting its intellectual property. Future success will be determined by the results of these trials and regulatory approvals.

iBio (IBIO) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 6 analysts, iBio (IBIO) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.